Smith+Nephew Expands Trauma Portfolio with SI-BONE Distribution Deal

Event summary

  • Smith+Nephew signed a distribution agreement with SI-BONE for the iFuse TORQ portfolio, focusing on pelvic fracture fixation and SI joint fusion.
  • The deal expands Smith+Nephew's offerings in high-frequency trauma procedures.
  • iFuse TORQ TNT has FDA Breakthrough Device Designation and NTAP eligibility, providing up to $4,136 in additional Medicare reimbursement per procedure.
  • Smith+Nephew will leverage SI-BONE's sales channel to serve surgeons and patients in this high-need area.

The big picture

This partnership aligns with Smith+Nephew's strategy of portfolio optimization in high-impact trauma procedures. The deal strengthens its position in the growing market for minimally invasive pelvic fracture solutions, where procedural volumes have been rising due to an aging population and increasing sports-related injuries. The inclusion of NTAP-eligible devices could further accelerate adoption by hospitals seeking higher reimbursement.

What we're watching

Revenue Synergies
How the integration of SI-BONE's iFuse TORQ portfolio will impact Smith+Nephew's trauma and extremities revenue.
Regulatory Advantage
Whether the FDA Breakthrough Device Designation and NTAP eligibility will drive faster adoption of iFuse TORQ TNT.
Market Penetration
The pace at which Smith+Nephew can expand access to the iFuse TORQ portfolio through its established commercial platform.

Related topics

Medical Devices